Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

General Endocrinology

Point-of-Care COVID-19 Test Delivers Results Within Minutes

Diana Ernst, RPh

April 1, 2020

The FDA has issued an Emergency Use Authorization for the Abbott ID Now™ COVID-19 test.

Practice Management

Update on REMS-Required Testing During COVID-19 Pandemic

Diana Ernst, RPh

April 1, 2020

For patients suspected of having COVID-19, undergoing REMS-required testing to obtain a medication may put others at risk.

Adrenal

Novel Therapy for Cushing Disease Receives FDA Approval

Diana Ernst, RPh

March 16, 2020

The Food and Drug Administration (FDA) has approved Isturisa® (osilodrostat; Recordati) for the treatment of adults with Cushing disease for whom pituitary surgery is not an option or has not been curative.

General Endocrinology

CDC Updates Guidance on Evaluating, Testing for COVID-19 as More Tests Become Available

Diana Ernst, RPh

March 16, 2020

The Centers for Disease Control and Prevention has updated the guidance for evaluation of persons under investigation for coronavirus disease 2019 (COVID-19), expanding the criteria to a wider group of symptomatic patients.

Type 2 Diabetes

Liquid Formulation of Extended-Release Metformin Now Available

Diana Ernst, RPh

March 2, 2020

Riomet ER™ oral suspension, a liquid formulation of extended-release metformin, has been made available by Sun Pharma.

Type 2 Diabetes

Dulaglutide Approved to Reduce Risk for Major Adverse Cardiovascular Events

Diana Ernst, RPh

February 27, 2020

The FDA has approved Trulicity (dulaglutide; Lilly) to reduce the risk of major adverse cardiovascular events (MACE; cardiovascular death, nonfatal myocardial infarction [MI], or nonfatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.

General Endocrinology

FDA Approves New Contraceptive Patch

Diana Ernst, RPh

February 24, 2020

The FDA has approved Twirla (levonorgestrel and ethinyl estradiol) transdermal system (Agile Therapeutics) as a method of contraception for use in women of reproductive potential with a body mass index (BMI) <30kg/m2 for whom a combined hormonal contraceptive is appropriate.